Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Myelodysplastic Syndrome Therapeutics Clinical Trials 28
Prominent Drugs 30
Latest Clinical Trials News on Myelodysplastic Syndrome 31
Nov 24, 2015: CTI BioPharma Announces United Kingdom National Cancer Research Institute AML
Cooperative Group Advances Tosedostat to Next Stage of "Pick-a-Winner" LI-1 Trial for Older
Patients with AML or High-Risk MDS 31
Nov 12, 2015: INNATE PHARMA: New combination trial with lirilumab in hemato-oncology 31
Nov 09, 2015: TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at
the 57th Annual American Society of Hematology Annual Meeting 32
Nov 05, 2015: MEI Pharma Highlights New Data from Phase II Clinical Studies of Pracinostat in Acute
Myeloid Leukemia and Myelodysplastic Syndrome 32
Nov 05, 2015: Onconova Announces Data Presentation From Phase 2 Combination Trial of Oral
Rigosertib and Azacitidine at the 2015 ASH Annual Meeting 33
Nov 05, 2015: Geron Announces Presentations at American Society of Hematology Annual Meeting
33
Oct 23, 2015: Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at
Research and Development Day Event 34
Sep 10, 2015: BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel
Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia 34
Clinical Trial Profile Snapshots 36
Appendix 1244
Abbreviations 1244
Definitions 1244
Research Methodology 1245
Secondary Research 1245
About GlobalData 1246
Contact Us 1246
Disclaimer 1246
Source 1247
Companies mentioned
Celgene Corporation
Novartis AG
Sanofi
Johnson & Johnson
Merck & Co., Inc.
Groupe Francophone des Myelodysplasies
Pfizer Inc.
Onconova Therapeutics, Inc.
Amgen Inc.
Eisai Co., Ltd.